Why the study?
Does DL-alpha-tocopherol acetate reduce platelet aggregation and TXA2 production in type I diabetic patients?
Population
22 type I diabetic patients without macroangiopathy and with no or only minimal microangiopathy
Comparison
DL-alpha-tocopherol acetate 400 mg daily for 4… vs Placebo (crossover design)
Design
RCT, Double-blind
Follow-up
4 weeks
Authors
Loading...
Vitamin E supplementation may reduce TXA2-driven platelet activity in type 1 diabetes; extends prior observational links in an RCT.
Does DL-alpha-tocopherol acetate reduce platelet aggregation and TXA2 production in type I diabetic patients?
Vitamin E supplementation (400 mg daily) significantly reduces platelet TXA2 production in type I diabetic patients, suggesting a potential mechanistic benefit for preventing diabetic angiopathy.
Gisinger et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: